Schering AG/Epix Contrast Agent Vasovist Gains EU Approval, Waits For FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Vasovist (formerly MS-235) has a U.S. user fee date of Nov. 23; FDA had requested efficacy data from new clinical trials.
You may also be interested in...
FDA Denies Epix Appeal, Asks For New Vasovist Trials
Epix may raise the level of its appeal on the imaging agent to FDA’s Center for Drug Evaluation & Research.
FDA Denies Epix Appeal, Asks For New Vasovist Trials
Epix may raise the level of its appeal on the imaging agent to FDA’s Center for Drug Evaluation & Research.
Epix Says FDA Will Take More Time to Review Vasovist Appeal
Company expects to hear a response to the appeal from agency in September.